S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:EIGR

Eiger BioPharmaceuticals - EIGR News Today

$9.30
-0.11 (-1.17%)
(As of 08/18/2022 05:45 PM ET)
Add
Compare
Today's Range
$8.97
$9.49
50-Day Range
$4.99
$9.66
52-Week Range
$3.53
$10.02
Volume
230,361 shs
Average Volume
612,257 shs
Market Capitalization
$408.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Get Eiger BioPharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

EIGR Media Mentions By Week

EIGR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EIGR
News Sentiment

1.29

0.63

Average
Medical
News Sentiment

EIGR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EIGR Articles
This Week

4

1

EIGR Articles
Average Week



SourceHeadline
MarketBeat logoEiger BioPharmaceuticals (NASDAQ:EIGR) Rating Increased to Hold at StockNews.com
americanbankingnews.com - August 10 at 1:42 AM
seekingalpha.com logoEiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 12:23 AM
finance.yahoo.com logoEiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
finance.yahoo.com - July 20 at 8:07 AM
uk.finance.yahoo.com logoAfter a strong run, what's next for investors in Eiger Biopharmaceuticals?
uk.finance.yahoo.com - July 10 at 6:30 PM
finance.yahoo.com logoEiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
finance.yahoo.com - June 27 at 8:25 PM
msn.com logoBest Skills For Eiger In Shadowrun: Dragonfall
msn.com - June 22 at 5:49 PM
morningstar.com logoEiger BioPharmaceuticals Inc - Stock Quote EIGR
morningstar.com - June 14 at 10:55 PM
finance.yahoo.com logoEiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries
finance.yahoo.com - June 13 at 11:47 AM
finance.yahoo.com logoEiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
finance.yahoo.com - June 8 at 9:12 AM
finance.yahoo.com logoEiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones
finance.yahoo.com - June 7 at 5:39 PM
finance.yahoo.com logoEMA's Advisory Committee Recommends Eiger's Zokinvy In Premature Aging Disorder
finance.yahoo.com - May 20 at 9:41 PM
marketwatch.com logoEiger Gets CHMP Backing for Zokinvy in Progeria >EIGR
marketwatch.com - May 20 at 11:40 AM
seekingalpha.com logoEU drug regulator panel recommends approval for Eiger BioPharma's progeria therapy
seekingalpha.com - May 20 at 11:40 AM
finance.yahoo.com logoEiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
finance.yahoo.com - May 20 at 11:40 AM
finance.yahoo.com logoThings Look Grim For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) After Today's Downgrade
finance.yahoo.com - May 12 at 9:57 AM
finance.yahoo.com logoEiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan
finance.yahoo.com - May 10 at 6:20 PM
seekingalpha.com logoEiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 10:23 AM
finance.yahoo.com logoShareholders in Eiger BioPharmaceuticals (NASDAQ:EIGR) are in the red if they invested three years ago
finance.yahoo.com - May 7 at 1:24 PM
finance.yahoo.com logoEiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 5 at 10:39 PM
seekingalpha.com logoEiger BioPharmaceuticals GAAP EPS of -$0.64 in-line, revenue of $2.67M misses by $1.38M
seekingalpha.com - May 5 at 5:38 PM
finance.yahoo.com logoEiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 5 at 5:38 PM
seekingalpha.com logoEiger BioPharmaceuticals Q1 2022 Earnings Preview
seekingalpha.com - May 4 at 9:27 PM
seekingalpha.com logoEiger avexitide shows promise in phase 2 trial in children with hyperinsulinism
seekingalpha.com - April 25 at 4:10 PM
markets.businessinsider.com logoEiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program
markets.businessinsider.com - April 25 at 9:48 AM
finance.yahoo.com logoEiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5
finance.yahoo.com - April 21 at 5:53 PM
seekingalpha.com logoEiger BioPharmaceuticals appoints Christopher Kurtz as Chief Technical Officer
seekingalpha.com - April 18 at 10:32 AM
seekingalpha.com logoEiger says COVID-19 therapy cut hospitalization risk by 50% in mostly vaccinated adults
seekingalpha.com - March 17 at 4:17 PM
finance.yahoo.com logoEiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
finance.yahoo.com - March 17 at 4:17 PM
finance.yahoo.com logoWhy Eiger BioPharmaceuticals Stock Is Jumping Today
finance.yahoo.com - March 17 at 4:17 PM
finance.yahoo.com logoNovartis and Roche Have Expensive Drugs That Scare Away Competitors
finance.yahoo.com - March 17 at 1:35 AM
finance.yahoo.com logoEiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022
finance.yahoo.com - March 16 at 8:35 PM
finance.yahoo.com logoThese Expensive Drugs Are Generating Billions for Pharma Giants
finance.yahoo.com - March 16 at 3:34 PM
finance.yahoo.com logoHere Are The 5 Most Expensive Drugs in the United States
finance.yahoo.com - March 16 at 10:33 AM
finance.yahoo.com logoEiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Just Slashed This Year's Estimates
finance.yahoo.com - March 15 at 7:28 PM
finance.yahoo.com logoIs Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - March 15 at 1:29 PM
finance.yahoo.com logoHow Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%
finance.yahoo.com - March 15 at 1:29 PM
seekingalpha.com logoEiger extends gains with no impact to trials in Russia and Ukraine
seekingalpha.com - March 14 at 4:38 PM
benzinga.com logoEiger BioPharmaceuticals's Return On Capital Employed Overview
benzinga.com - March 14 at 4:38 PM
benzinga.com logoEiger BioPharmaceuticals: Q4 Earnings Insights
benzinga.com - March 11 at 12:53 AM
seekingalpha.com logoEiger BioPharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 10 at 9:10 PM
seekingalpha.com logoEiger BioPharmaceuticals Q4 2021 Earnings Preview
seekingalpha.com - March 9 at 10:41 PM
finance.yahoo.com logoEiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10
finance.yahoo.com - February 24 at 8:09 PM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)?
finance.yahoo.com - February 14 at 12:12 PM
finance.yahoo.com logoPflug Koory, LLC Buys Vertex Pharmaceuticals Inc, Amgen Inc, NVIDIA Corp, Sells Adobe Inc, ...
finance.yahoo.com - January 20 at 1:44 PM
nasdaq.com logoWhat Kind Of Shareholders Hold The Majority In Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Shares?
nasdaq.com - January 10 at 8:24 AM
seekingalpha.com logoEiger Biopharmaceuticals provides pipeline updates for 2022
seekingalpha.com - January 6 at 3:50 PM
nasdaq.com logoEiger BioPharmaceuticals Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - December 30 at 8:21 AM
finance.yahoo.com logoThose who invested in Sempra (NYSE:SRE) five years ago are up 52%
finance.yahoo.com - December 23 at 1:38 PM
benzinga.com logoEiger BioPharmaceuticals Announces 1st Patient Enrolled In LIMT-2 Study
benzinga.com - December 21 at 7:04 PM
finance.yahoo.com logoIs Eiger BioPharmaceuticals (NASDAQ:EIGR) Using Debt Sensibly?
finance.yahoo.com - December 16 at 9:43 AM
Get Eiger BioPharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:EIGR) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.